Hologic Company Profile (NASDAQ:HOLX)

About Hologic (NASDAQ:HOLX)

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Industry, Sector and Symbol:

Sector: Medical
Industry: Advanced Medical Equipment & Technology
Sub-Industry: Health Care Equipment
Symbol: NASDAQ:HOLX
CUSIP: 43644010
Web: www.hologic.com

Capitalization:

Market Cap: $10.32423 billion
Outstanding Shares: 280,473,000

Average Prices:

50 Day Moving Avg: $37.55
200 Day Moving Avg: $41.76
52 Week Range: $35.15 - $46.80

P/E:

Trailing P/E Ratio: 13.74
Foreward P/E Ratio: 17.24
P/E Growth: 2.05

Sales & Book Value:

Annual Revenue: $2.98 billion
Price / Sales: 3.47
Book Value: $10.23 per share
Price / Book: 3.61

Profitability:

EBITDA: $1.01 billion
Net Margins: 25.65%
Return on Equity: 23.18%
Return on Assets: 7.39%

Debt:

Debt-to-Equity Ratio: 0.78%
Current Ratio: 0.85%
Quick Ratio: 0.65%

Misc:

Average Volume: 3.26 million shs.
Beta: 0.91
Short Ratio: 5.07

Frequently Asked Questions for Hologic (NASDAQ:HOLX)

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.01. The company earned $806.10 million during the quarter, compared to analysts' expectations of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. Hologic's revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.51 earnings per share. View Hologic's Earnings History.

When will Hologic make its next earnings announcement?

Hologic is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Hologic.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its fourth quarter earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of $0.48-0.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.50. The company issued revenue guidance of $785-800 million, compared to the consensus revenue estimate of $817.04 million.

Where is Hologic's stock going? Where will Hologic's stock price be in 2017?

13 brokers have issued twelve-month price targets for Hologic's stock. Their forecasts range from $42.00 to $53.00. On average, they anticipate Hologic's stock price to reach $47.77 in the next year. View Analyst Ratings for Hologic.

What are analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

1. According to Zacks Investment Research, "Hologic has been trading below the broader industry over the last six months. Moreover, the lowered guidance suggests dull prospects. Furthermore, the blood screening divestiture is expected to impede the company’s growth momentum in the days ahead. Foreign currency headwinds and a competitive landscape also continue to pose challenges. On a positive note, Hologic is optimistic about the recent commercial launch of the Brevera breast biopsy system in the United States. Hologic’s third-quarter 2017 performance was quite promising with revenues and earnings beating the estimates. The company’s top-line growth was led by strength in the molecular diagnostics and GYN Surgical businesses. Moreover, sales were driven by the company’s recent receipt of CE mark for its new Panther Fusion system and Panther Fusion assays for flu and respiratory testing." (10/17/2017)
2. Needham & Company LLC analysts commented, "FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 10/2/17. The number of digital breast tomosynthesis (DBT) units increased by 118 during September which represents a (4.1%) Y/Y decrease. DBT unit penetration increased to 28.5% from 28.0% last month and facility penetration increased to 42.8% from 42.0% last month. More importantly, DBT units placements were up 5.9% in F4Q17 vs. F4Q16. Based on this, we think that HOLX’s Breast Health business could see improved growth in F4Q17." (10/2/2017)

Who are some of Hologic's key competitors?

Some companies that are related to Hologic include Waters Corporation (WAT), ResMed (RMD), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Mazor Robotics (MZOR), Quidel Corporation (QDEL), Natus Medical Incorporated (BABY), Accelerate Diagnostics (AXDX), ABAXIS (ABAX), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), ViewRay (VRAY) and Accuray Incorporated (ARAY).

Who are Hologic's key executives?

Hologic's management team includes the folowing people:

Stephen P. MacMillan, Chairman of the Board, President, Chief Executive Officer
Robert W. McMahon, Chief Financial Officer
Sanjay Prabhakaran, Regional President - Asia
Peter J. Valenti III, Division President- Breast and Skeletal Health
Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
Thomas A. West, Division President- Diagnostics
Eric B. Compton, Chief Operating Officer
Michael J. Watts, Vice President, IR Contact Officer
John M. Griffin, General Counsel
Elaine S. Ullian, Lead Independent Director

Who owns Hologic stock?

Hologic's stock is owned by many different of retail and institutional investors. Top institutional investors include Curbstone Financial Management Corp (0.01%). Company insiders that own Hologic stock include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

Who bought Hologic stock? Who is buying Hologic stock?

Hologic's stock was acquired by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp. View Insider Buying and Selling for Hologic.

How do I buy Hologic stock?

Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of Hologic stock can currently be purchased for approximately $36.89.

MarketBeat Community Rating for Hologic (NASDAQ HOLX)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		525 (Vote Outperform)
Underperform Votes:		360 (Vote Underperform)
Total Votes:		885

MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Hologic (NASDAQ:HOLX) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	4 Hold Ratings, 9 Buy Ratings
Consensus Rating:	Buy (Score: 2.69)
Consensus Price Target:	$47.77 (29.49% upside)

Consensus Price Target History for Hologic (NASDAQ:HOLX)

Analysts' Ratings History for Hologic (NASDAQ:HOLX)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
10/10/2017	Jefferies Group LLC	Reiterated Rating	Buy	$49.00 -> $44.00	N/A
10/9/2017	Stifel Nicolaus	Reiterated Rating	Buy -> Buy	$48.00 -> $45.00	N/A
10/2/2017	Needham & Company LLC	Reiterated Rating	Buy	$50.00	Medium
9/22/2017	Royal Bank Of Canada	Reiterated Rating	Hold	$42.00	Low
8/9/2017	Barclays PLC	Reiterated Rating	Equal Weight	$53.00 -> $51.00	Low
8/3/2017	Deutsche Bank AG	Lower Price Target	Buy	$51.00 -> $49.00	Medium
8/3/2017	Goldman Sachs Group, Inc. (The)	Downgrade	Conviction-Buy -> Buy	$48.00 -> $47.00	High
7/21/2017	Bank of America Corporation	Reiterated Rating	Neutral	$44.00 -> $48.00	Low
7/14/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$51.00	Medium
5/14/2017	BTIG Research	Reiterated Rating	Buy	$47.00	Low
5/9/2017	Canaccord Genuity	Reiterated Rating	Buy	$53.00	Low
3/30/2017	Leerink Swann	Reiterated Rating	Outperform	$52.00	Low
1/4/2017	Evercore ISI	Downgrade	Buy -> Hold	$42.00	N/A
7/28/2016	Morgan Stanley	Boost Price Target	Equal Weight	$38.00 -> $40.00	N/A
1/31/2016	William Blair	Reiterated Rating	Outperform		N/A
1/28/2016	J P Morgan Chase & Co	Reiterated Rating	Buy		N/A
10/26/2015	Gabelli	Initiated Coverage	Buy	$43.00	N/A
10/21/2015	Craig Hallum	Downgrade	Buy -> Hold	$42.00 -> $37.00	N/A

(Data available from 10/19/2015 forward)

Earnings History for Hologic (NASDAQ:HOLX)

Earnings by Quarter for Hologic (NASDAQ:HOLX)

Earnings History by Quarter for Hologic (NASDAQ HOLX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/8/2017		$0.49					N/A
8/2/2017	Q3 2017	$0.49	$0.50	$799.70 million	$806.10 million	View	Listen
5/10/2017	Q2 17	$0.46	$0.50	$685.24 million	$715.40 million	View	N/A
2/1/2017	Q117	$0.51	$0.52	$725.01 million	$734.40 million	View	Listen
11/2/2016	Q416	$0.50	$0.52	$721.52 million	$726.80 million	View	N/A
7/27/2016	Q316	$0.48	$0.51	$703.66 million	$717.40 million	View	Listen
4/27/2016	Q216	$0.46	$0.47	$686.82 million	$693.30 million	View	Listen
1/27/2016	Q116	$0.42	$0.46	$688.68 million	$695.20 million	View	Listen
11/4/2015	Q415	$0.42	$0.43	$691.94 million	$702.80 million	View	Listen
7/29/2015	Q315	$0.39	$0.43	$653.85 million	$693.90 million	View	Listen
4/29/2015	Q215	$0.39	$0.41	$646.49 million	$655.50 million	View	N/A
1/28/2015	Q115	$0.36	$0.39	$630.79 million	$652.80 million	View	Listen
11/5/2014	Q414	$0.37	$0.43	$636.20 million	$660.60 million	View	Listen
7/30/2014	Q314	$0.34	$0.37	$621.89 million	$632.60 million	View	Listen
4/30/2014	Q214	$0.33	$0.37	$609.35 million	$625.00 million	View	Listen
2/3/2014	Q114	$0.31	$0.34	$609.65 million	$612.40 million	View	Listen
11/11/2013	Q413	$0.37	$0.39	$624.40 million	$622.10 million	View	Listen
8/5/2013	Q3 2013	$0.37	$0.38	$627.05 million	$626.10 million	View	Listen
5/6/2013	Q2 2013	$0.34	$0.35	$639.53 million	$619.10 million	View	Listen
2/4/2013	Q1 2013	$0.37	$0.38	$646.52 million	$644.60 million	View	Listen
11/12/2012	Q412	$0.36	$0.37	$581.12 million	$600.20 million	View	N/A
7/30/2012		$0.34	$0.35			View	N/A
4/30/2012		$0.33	$0.33			View	N/A
1/30/2012		$0.32	$0.34			View	N/A
11/7/2011		$0.33	$0.34			View	N/A
8/1/2011		$0.32	$0.32			View	N/A
5/2/2011		$0.28	$0.30			View	N/A
1/31/2011		$0.28	$0.30			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Hologic (NASDAQ:HOLX)

2017 EPS Consensus Estimate: $2.00
2018 EPS Consensus Estimate: $2.12

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	4	$0.50	$0.51	$0.51
Q2 2017	3	$0.46	$0.53	$0.49
Q3 2017	3	$0.48	$0.54	$0.50
Q4 2017	4	$0.49	$0.55	$0.51
Q1 2018	3	$0.52	$0.52	$0.52
Q2 2018	3	$0.52	$0.55	$0.53
Q3 2018	3	$0.51	$0.57	$0.54
Q4 2018	3	$0.52	$0.55	$0.53

(Data provided by Zacks Investment Research)

Dividend History for Hologic (NASDAQ:HOLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Hologic (NASDAQ:HOLX)

Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 96.38%

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Insider Trades by Quarter for Hologic (NASDAQ:HOLX)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
10/10/2017	Lawrence M Levy	Director	Sell	9,596	$36.81	$353,228.76
10/9/2017	Lawrence M Levy	Director	Sell	7,138	$37.38	$266,818.44
9/7/2017	Lawrence M. Levy	Director	Sell	7,139	$39.04	$278,706.56
8/3/2017	Elaine Ullian	Director	Sell	6,902	$40.12	$276,908.24
7/17/2017	Karleen Marie Oberton	VP	Sell	4,704	$45.19	$212,573.76
7/3/2017	Elaine Ullian	Director	Sell	8,849	$45.28	$400,682.72
6/7/2017	Lawrence M Levy	Director	Sell	2,960	$44.54	$131,838.40
6/2/2017	Elaine Ullian	Director	Sell	8,938	$43.99	$393,182.62
5/30/2017	Peter J Valenti III	Insider	Sell	10,005	$43.44	$434,617.20
5/24/2017	Lawrence M Levy	Director	Sell	9,193	$42.93	$394,655.49
5/17/2017	Lawrence M Levy	Director	Sell	9,076	$42.80	$388,452.80
5/10/2017	Lawrence M Levy	Director	Sell	9,837	$45.34	$446,009.58
5/3/2017	Lawrence M Levy	Director	Sell	10,203	$45.00	$459,135.00
4/26/2017	Lawrence M Levy	Director	Sell	10,374	$44.46	$461,228.04
4/24/2017	Sally Crawford	Director	Sell	16,969	$44.00	$746,636.00
4/19/2017	Lawrence M Levy	Director	Sell	10,836	$42.49	$460,421.64
4/12/2017	Lawrence M Levy	Director	Sell	10,757	$42.45	$456,634.65
4/3/2017	Elaine Ullian	Director	Sell	9,104	$42.40	$386,009.60
3/8/2017	Sally Crawford	Director	Sell	17,396	$42.00	$730,632.00
2/3/2017	Elaine Ullian	Director	Sell	9,423	$39.54	$372,585.42
11/21/2016	Karleen Marie Oberton	VP	Sell	3,023	$38.32	$115,841.36
11/15/2016	Karleen Marie Oberton	VP	Sell	1,211	$36.55	$44,262.05
11/8/2016	Karleen Marie Oberton	VP	Sell	984	$38.57	$37,952.88
11/7/2016	Karleen Marie Oberton	VP	Sell	522	$38.53	$20,112.66
10/10/2016	Elaine Ullian	Director	Sell	18,236	$39.88	$727,251.68
10/10/2016	Karleen Marie Oberton	VP	Sell	31,470	$40.00	$1,258,800.00
7/21/2016	Nancy Leaming	Director	Sell	8,179	$37.00	$302,623.00
7/11/2016	Nancy Leaming	Director	Sell	6,221	$36.04	$224,204.84
6/1/2016	Lawrence M Levy	Director	Sell	17,794	$34.41	$612,291.54
5/27/2016	Peter J Valenti III	Insider	Sell	10,022	$33.83	$339,044.26
5/26/2016	Elaine Ullian	Director	Sell	6,896	$33.85	$233,429.60
5/26/2016	Karleen Marie Oberton	VP	Sell	4,228	$33.85	$143,117.80
2/24/2016	David R Lavance Jr	Director	Sell	11,621	$34.50	$400,924.50
11/10/2015	Lawrence M. Levy	Director	Sell	20,000	$40.70	$814,000.00
9/21/2015	Lawrence M. Levy	Director	Sell	5,000	$42.02	$210,100.00
9/8/2015	Wayne Wilson	Director	Sell	100,000	$39.00	$3,900,000.00
8/28/2015	Wayne Wilson	Director	Sell	11,146	$39.70	$442,496.20
8/26/2015	Wayne Wilson	Director	Sell	25,080	$38.61	$968,338.80
8/14/2015	Wayne Wilson	Director	Sell	13,257	$42.20	$559,445.40
6/3/2015	Lawrence M Levy	Director	Sell	10,000	$36.45	$364,500.00
5/22/2015	Lawrence M Levy	Director	Sell	5,000	$35.05	$175,250.00
5/4/2015	Lawrence M Levy	Director	Sell	10,000	$34.36	$343,600.00
3/6/2015	David R Lavance Jr	Director	Sell	12,000	$32.12	$385,440.00
2/13/2015	David R Lavance Jr	Director	Sell	8,000	$30.32	$242,560.00
1/29/2015	Karleen Marie Oberton	VP	Sell	18,997	$30.00	$569,910.00
11/11/2014	Karleen Marie Oberton	VP	Sell	2,609	$26.30	$68,616.70
11/3/2014	Karleen Marie Oberton	VP	Sell	12,507	$26.83	$335,562.81
10/31/2014	Roger D Mills	SVP	Sell	14,506	$26.00	$377,156.00
9/9/2014	Elaine Ullian	Director	Buy	7,900	$25.36	$200,344.00
5/9/2014	Rohan Hastie	SVP	Sell	6,037	$24.36	$147,061.32
5/8/2014	Glenn Muir	CFO	Sell	50,000	$24.26	$1,213,000.00
5/6/2014	Glenn Muir	CFO	Sell	196,000	$23.29	$4,564,840.00
5/6/2014	Lawrence Levy	Director	Sell	5,052	$23.58	$119,126.16
5/6/2014	Robert Lavallee	CAO	Sell	22,796	$23.58	$537,529.68
3/14/2014	David Lavance, Jr.	Director	Sell	5,500	$21.49	$118,195.00
3/14/2014	Glenn Muir	CFO	Sell	160,000	$21.51	$3,441,600.00
3/7/2014	Mark Casey	CAO	Sell	3,251	$22.53	$73,245.03
2/11/2014	Stephen Macmillan	CEO	Buy	38,600	$21.58	$832,988.00
2/7/2014	Stephen Macmillan	CEO	Buy	198,900	$20.78	$4,133,142.00
12/13/2013	Robert Lavallee	CAO	Sell	15,677	$21.70	$340,190.90
10/30/2013	Glenn P Muir	CFO	Sell	140,000	$22.32	$3,124,800.00
10/15/2013	Glenn P Muir	CFO	Sell	28,000	$22.12	$619,360.00
9/16/2013	Glenn Muir	CFO	Sell	28,000	$20.45	$572,600.00
9/13/2013	Robert Lavallee	CAO	Sell	2,500	$20.33	$50,825.00
8/20/2013	David Brady	SVP	Sell	42,328	$22.80	$965,078.40
8/15/2013	Glenn Muir	CFO	Sell	28,000	$22.49	$629,720.00
8/8/2013	Lawrence Levy	Director	Sell	5,000	$22.50	$112,500.00
8/8/2013	Mark Casey	CAO	Sell	14,804	$22.57	$334,126.28
7/19/2013	Robert H Lavallee	CAO	Sell	11,254	$20.89	$235,096.06
7/15/2013	Glenn P Muir	CFO	Sell	28,000	$19.78	$553,840.00
7/1/2013	Robert Cascella	CEO	Sell	20,000	$19.55	$391,000.00
6/17/2013	Glenn P Muir	CFO	Sell	28,000	$21.42	$599,760.00
6/3/2013	Robert Cascella	CEO	Sell	20,000	$20.71	$414,200.00
2/25/2013	Lawrence M Levy	Director	Sell	5,000	$22.00	$110,000.00
9/5/2012	Glenn P Muir	CFO	Sell	68,750	$19.96	$1,372,250.00
8/8/2012	Glenn P Muir	CFO	Sell	68,750	$19.69	$1,353,687.50

(Data available from 1/1/2013 forward)

Headline Trends for Hologic (NASDAQ:HOLX) Latest Headlines for Hologic (NASDAQ:HOLX)

Source:

Date	Headline
	15 Cheap Stocks That Could Launch the 'Next Big Thing' finance.yahoo.com - October 19 at 2:34 AM
	Head to Head Comparison: Hologic (HOLX) and Its Peers www.americanbankingnews.com - October 17 at 10:26 PM
	Hologic, Inc. (HOLX) Downgraded by Zacks Investment Research to Sell www.americanbankingnews.com - October 17 at 3:32 PM
	Q1 2018 Earnings Forecast for Hologic, Inc. Issued By Leerink Swann (HOLX) www.americanbankingnews.com - October 16 at 5:38 AM
	Analyzing Hologic (HOLX) & Its Rivals www.americanbankingnews.com - October 16 at 2:10 AM
	Brokers Set Expectations for Hologic, Inc.'s FY2018 Earnings (HOLX) www.americanbankingnews.com - October 13 at 1:30 PM
	Insider Selling: Hologic, Inc. (HOLX) Director Sells 9,596 Shares of Stock www.americanbankingnews.com - October 12 at 7:26 PM
	Equities Analysts Issue Forecasts for Hologic, Inc.'s Q1 2018 Earnings (HOLX) www.americanbankingnews.com - October 11 at 10:12 AM
	Hologic, Inc. (HOLX) Director Sells $266,818.44 in Stock www.americanbankingnews.com - October 10 at 7:38 PM
	Hologic, Inc. (HOLX) Receives "Buy" Rating from Jefferies Group LLC www.americanbankingnews.com - October 10 at 2:34 PM
	Stifel Nicolaus Lowers Hologic, Inc. (HOLX) Price Target to $45.00 www.americanbankingnews.com - October 9 at 8:16 AM
	Hologic, Inc. (HOLX) Receives Average Recommendation of "Hold" from Brokerages www.americanbankingnews.com - October 8 at 9:00 AM
	Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval - Nasdaq www.nasdaq.com - October 6 at 8:02 PM
	Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval finance.yahoo.com - October 6 at 8:01 PM
	Analysts Anticipate Hologic, Inc. (HOLX) Will Post Earnings of $0.49 Per Share www.americanbankingnews.com - October 6 at 4:36 PM
	Hologic (HOLX) Says Panther Fusion Flu A/B/RSV Assay is Now FDA Cleared www.streetinsider.com - October 6 at 8:02 AM
	Hologic (HOLX) Says Panther Fusion Flu A/B/RSV Assay is Now FDA Cleared - StreetInsider.com www.streetinsider.com - October 5 at 7:57 PM
	Panther Fusion® Flu A/B/RSV Assay Now FDA Cleared on Hologic's New Panther Fusion® System finance.yahoo.com - October 5 at 7:57 PM
	Hologic, Inc. -- Moody's assigns Ba3 to Hologic's senior unsecured bonds finance.yahoo.com - October 5 at 2:56 PM
	Hologic Announces Pricing of Offering of $350 Million Aggregate Principal Amount of 4.375% Senior Notes Due 2025 finance.yahoo.com - October 5 at 2:56 PM
	Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2017 on Wednesday, November 8, 2017 finance.yahoo.com - October 4 at 9:20 AM
	Hologic Enters into Amended and Restated Five-Year Secured Credit Agreement finance.yahoo.com - October 4 at 9:20 AM
	Hologic Announces Offering of $350 Million of Senior Notes Due 2025 finance.yahoo.com - October 4 at 9:20 AM
	Is Hologic Inc’s (HOLX) PE Ratio A Signal To Buy For Investors? finance.yahoo.com - October 4 at 9:20 AM
	Hologic, Inc. -- Moody's assigns Ba1 to Hologic's senior secured credit facility finance.yahoo.com - October 4 at 9:20 AM
	Hologic, Inc. (HOLX) Given Buy Rating at Needham & Company LLC www.americanbankingnews.com - October 2 at 4:30 PM
	Hologic CEO: Next-gen mammograms improve patient experien... finance.yahoo.com - October 2 at 1:32 PM
	Hologic, Inc. (Nasdaq: HOLX) to Ring The Nasdaq Stock Market Opening Bell www.nasdaq.com - September 29 at 4:49 PM
	Hologic CEO Steve MacMillan to Ring Nasdaq Opening Bell on October 2 to Kick Off Breast Cancer Awareness Month www.bizjournals.com - September 29 at 10:19 AM
	Hologic Introduces a More Comfortable Mammogram with the Launch of the SmartCurve™ Breast Stabilization System www.bizjournals.com - September 28 at 12:59 PM
	Hologic, Inc. (HOLX) Receives Hold Rating from Royal Bank Of Canada www.americanbankingnews.com - September 22 at 9:38 PM
	$792.67 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter www.americanbankingnews.com - September 19 at 1:16 AM
	New USPSTF Draft Cervical Cancer Screening Recommendations Are a Step Back for Women's Health, Would Put Lives at Risk finance.yahoo.com - September 14 at 8:27 PM
	Financial Survey: Hologic (HOLX) versus Intuitive Surgical (ISRG) www.americanbankingnews.com - September 13 at 4:44 PM
	Hologic, Inc. (HOLX) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - September 13 at 9:34 AM
	William Blair Weighs in on Hologic, Inc.'s Q4 2017 Earnings (HOLX) www.americanbankingnews.com - September 13 at 9:02 AM
	Hologic (HOLX) Down 11.1% Since Earnings Report: Can It Rebound? - Nasdaq www.nasdaq.com - September 12 at 11:32 PM
	Hologic, Inc. (HOLX) Director Sells $278,706.56 in Stock www.americanbankingnews.com - September 11 at 7:50 PM
	Hologic (HOLX) Down 11.1% Since Earnings Report: Can It Rebound? finance.yahoo.com - September 11 at 4:39 AM
	GMAC Commercial Mortgage Securities, Inc. Series 2003-C1 -- Moody's Affirms Five Classes of GMACC 2003-C1 finance.yahoo.com - September 8 at 8:07 PM
	Hologic (HOLX) Launches Brevera, Progresses in Breast Health - Nasdaq www.nasdaq.com - September 6 at 6:08 AM
	Analysts Expect Hologic, Inc. (HOLX) Will Announce Quarterly Sales of $792.68 Million www.americanbankingnews.com - September 1 at 9:22 PM
	Hologic Announces Availability of New Brevera® Breast Biopsy System with CorLumina® Imaging Technology finance.yahoo.com - August 31 at 7:29 PM
	Kahn Brothers Curbs Hologic, Citigroup, Pfizer Postitions, Exits GE finance.yahoo.com - August 31 at 5:50 AM
	Hologic Enters Oversold Territory (HOLX) www.nasdaq.com - August 28 at 7:12 PM
	Hologic, Inc. (HOLX) Short Interest Down 13.8% in August www.americanbankingnews.com - August 27 at 3:12 AM
	After Hours Most Active for Aug 22, 2017 : CPN, CRM, QQQ, KO, AAPL, SBUX, T, MU, TGT, XOM, CSCO, HOLX - Nasdaq www.nasdaq.com - August 23 at 12:58 AM
	Critical Survey: Hologic (HOLX) vs. Invivo Therapeutics Holdings Corp (NVIV) www.americanbankingnews.com - August 21 at 4:22 AM
	Hologic, Inc. (HOLX) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - August 19 at 9:12 AM
	Hologic, Inc. – Value Analysis (NASDAQ:HOLX) : August 12, 2017 finance.yahoo.com - August 12 at 6:38 PM